Multiple Dose Study to Determine Safety and Tolerability of ESK-001 in Healthy Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Safety and Tolerability

In brief

Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants

Key facts

Study ID

NCT05431634

Run by

Alumis Inc

People needed

49

Starts

2022-05-12

Expected to finish

2022-12-31

Last updated by the study team

2023-05-09

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Participant is a man or woman between the ages of 18 and 60years, inclusive, at the Screening Visit
• Participant is healthy as determined by medical history, physical examination, vital signs, and routine laboratory parameters
• Other inclusions as specified in the protocol

You may not qualify if…

• Participant has a prior exposure to ESK-001
• Participant has a history of hypersensitivity to any of the ingredients of ESK-001
• Other exclusions as specified in the protocol

Where it is running

• Alumis Central site — Glendale, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.